Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to "Buy" at Wall Street Zen

Key Points

• Bayer Aktiengesellschaft has been upgraded from a "hold" rating to a "buy" rating by Wall Street Zen following previous upgrades from Kepler Capital Markets and Goldman Sachs.
• The company's stock is currently trading at $7.53 with a market capitalization of $29.59 billion and an average rating of "Buy" from analysts.
• Bayer's recent quarterly earnings report showed an EPS of $0.35, surpassing expectations, with revenues of $12.42 billion compared to the consensus estimate of $10.79 billion.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Sunday.

Several other equities analysts have also weighed in on BAYRY. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 11th. Kepler Capital Markets raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. Finally, The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. One research analyst has rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

OTCMKTS BAYRY traded down $0.10 on Friday, hitting $7.72. 2,051,913 shares of the stock traded hands, compared to its average volume of 1,358,658. The business's fifty day moving average is $7.86 and its two-hundred day moving average is $6.79. Bayer Aktiengesellschaft has a 12 month low of $4.79 and a 12 month high of $8.65. The firm has a market capitalization of $30.34 billion, a price-to-earnings ratio of -7.96 and a beta of 0.91. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.79 and a current ratio of 1.25.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.10. Bayer Aktiengesellschaft had a positive return on equity of 15.48% and a negative net margin of 7.61%. The business had revenue of $12.42 billion during the quarter, compared to analyst estimates of $10.79 billion. As a group, equities analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.